How should a lidocaine infusion infiltration at a peripheral intravenous (IV) line be treated?

Management of Lidocaine Infusion Infiltration at Peripheral IV Line

Immediately stop the infusion, remove the IV catheter, elevate the affected extremity, and observe closely—the vast majority of peripheral IV infiltrations, including lidocaine, resolve with elevation and observation alone without requiring invasive intervention.

Immediate Actions

When lidocaine infiltration is suspected at a peripheral IV site, take the following steps:

1. Stop and Assess

• Discontinue the infusion immediately and remove the IV catheter
• Assess the infiltration site for:
  • Swelling, coolness, blanching, or pain at the site
  • Extent of tissue involvement
  • Signs of vascular compromise
  • Patient symptoms (peri-oral tingling, tinnitus, light-headedness, restlessness—early signs of systemic lidocaine toxicity) 1

2. Initial Management

• Elevate the affected extremity above heart level
• Apply warm compresses to improve tissue perfusion and prevent progression of tissue necrosis 2
• Document the infiltration volume (if known), concentration, and time of occurrence
• Monitor vital signs closely for signs of systemic toxicity

3. Monitor for Systemic Toxicity

Even with infiltration, systemic absorption can occur. Watch for:

• Neurological symptoms (earliest signs): peri-oral tingling, tinnitus, light-headedness, restlessness, euphoria, facial flushing 1
• Cardiovascular signs (late manifestations): arrhythmias, myocardial depression, cardiac arrest 1
• Ensure lipid emulsion 20% is readily available for potential local anesthetic systemic toxicity (LAST) treatment 1

Clinical Decision Algorithm

Low-Risk Infiltration (Most Cases)

If the patient has:

• Minimal swelling (<5 cm diameter)
• No skin changes (blanching, coolness, discoloration)
• No systemic symptoms
• No signs of compartment syndrome

Management:

• Elevation and observation by nursing staff
• Reassess every 15 minutes for the first hour, then hourly 1
• No specialist consultation needed 3, 4

Moderate-Risk Infiltration

If the patient has:

• Moderate swelling (5-10 cm diameter)
• Mild skin changes (blanching, coolness)
• Persistent pain despite elevation
• No systemic symptoms

Management:

• Continue elevation and warm compresses
• Involve wound care team for assessment 3
• Consider photography for documentation
• Continue close monitoring
• Specialist consultation typically not required 4

High-Risk Infiltration (Rare)

If the patient has:

• Extensive swelling (>10 cm diameter)
• Significant skin changes (blistering, necrosis, eschar formation)
• Signs of compartment syndrome (severe pain, tense compartment, neurovascular compromise)
• Systemic toxicity symptoms

Management:

• Immediate consultation with plastic surgery or hand surgery
• Continue elevation and supportive care
• Prepare for potential bedside procedures (aspiration) or surgical intervention if compartment syndrome develops 3
• Have lipid emulsion ready for LAST protocol 1

Evidence-Based Outcomes

Recent data from 495 IV infiltration events at a tertiary care center showed 3:

• 91-93% resolve with elevation and observation alone 3, 4
• Only 8.6% developed superficial soft tissue infection
• Only 3.2% developed necrosis or eschar formation
• Only 1.9% developed ulceration or full-thickness wounds
• Zero cases of compartment syndrome
• Only 5.1% resulted in any long-term defects; none resulted in functional deficits
• Only 1.4% required any surgical intervention (none emergent)

Critical Pitfalls to Avoid

1. Do not perform invasive interventions routinely: Aspiration, incision, or antidote injection is almost never indicated and was used in only 2% of cases 4

2. Do not delay recognition of systemic toxicity: Neurological symptoms precede cardiovascular collapse—early recognition is critical 1

3. Do not assume vascular disease worsens outcomes: Patients with peripheral vascular disease did not experience worse outcomes compared to healthy individuals in large series 3

4. Do not over-consult specialists: While 25.3% of infiltrations prompted specialist consultation, none were surgical emergencies 3. Most can be managed by primary nursing staff and wound care teams 4

5. Do not forget documentation: Accurate documentation is vital for patient care continuity and potential litigation 5

Special Considerations for Lidocaine

Unlike vesicant chemotherapy agents, lidocaine is not classified as a vesicant requiring specific antidotes. The international consensus statement emphasizes prevention through proper administration technique 1:

• Lidocaine should be delivered through a dedicated, separate cannula
• Minimum flush of 0.9% sodium chloride at 10 ml/h to prevent tracking 1
• One-way valve to prevent retrograde flow 1

The primary concern with lidocaine infiltration is the potential for systemic absorption leading to toxicity, rather than local tissue damage, which distinguishes it from true vesicant infiltrations 6.